Loading…
Loading…
EQUITY / NASDAQ · XNCM
InMed Pharmaceuticals Inc.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →07/01/2025 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.33 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.33 USD · Volume 28,341
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
07/01/2025 – 06/30/2026 · Units
| Metric | 2026 / Year end | 2025 / Year end | Change |
|---|---|---|---|
| Net income | -12,560,850 USD | -8,162,133 USD | — |
| Operating cash flow | -8,643,513 USD | -8,099,392 USD | — |
| Total liabilities | 1,955,060 USD | 2,145,545 USD | -8.88% |
| Total equity | 1,075,007 USD | 13,434,495 USD | -92.00% |
| Financing cash flow | 94,496 USD | 12,271,212 USD | -99.23% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Year end07/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 207/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 306/30/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Financing cash flowCash flow statement | 94,496 USD | — | 94,497 USD | — | -137,178 USD | — | 12,271,212 USD | — |
| Net incomeIncome statement | -12,560,850 USD | -2,966,336 USD | -6,721,458 USD | -2,028,223 USD | -3,755,122 USD | -1,726,899 USD | -8,162,133 USD | — |
| Operating cash flowCash flow statement | -8,643,513 USD | — | -5,678,995 USD | — | -3,983,859 USD | — | -8,099,392 USD | — |
| Total assetsBalance sheet | 3,030,067 USD | 9,133,806 USD | — | — | — | — | 15,580,040 USD | 15,580,040 USD |
| Total equityBalance sheet | 1,075,007 USD | 6,891,774 USD | — | 9,587,664 USD | — | 11,590,623 USD | 13,434,495 USD | 13,434,495 USD |
| Total liabilitiesBalance sheet | 1,955,060 USD | 2,242,032 USD | — | — | — | — | 2,145,545 USD | 2,145,545 USD |
| Cash and cash equivalentsBalance sheet | — | 5,158,932 USD | — | — | — | — | — | 10,743,430 USD |
| Gross profitIncome statement | — | — | — | — | 587,353 USD | — | — | — |
| RevenueIncome statement | — | — | — | — | 1,940,309 USD | — | — | — |
| Report source | Open report ↗ Published: 09/09/2026 | Open report ↗ Published: 05/06/2026 | Open report ↗ Published: 05/06/2026 | Open report ↗ Published: 05/06/2026 | Open report ↗ Published: 02/11/2026 | Open report ↗ Published: 05/06/2026 | Open report ↗ Published: 09/09/2026 | Open report ↗ Published: 05/06/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.